Access and Health Equity

A Biogen employee shares education materials about diseases with a person.

Our approach to providing equitable access is focused on helping people who are underrepresented or underserved gain access to quality health care at every stage of the patient journey. This involves seeing each patient not as a profile, but as a person.

Advancing Health Access

We are continuously evolving our thinking and approaches to ensure broad access to our therapies. People who meet specific criteria may have access to investigational therapies through clinical trials, Early Access Programs or compassionate use based on humanitarian grounds.

Diversifying Clinical Trials

Health outcomes often depend on factors beyond the control of people and their doctors, such as disparities across age, gender, race, ethnicity, geographic locations globally and socioeconomic level. These disparities are compounded by factors ranging from inadequate representation in clinical trials to barriers to accessing care. We are committed to addressing health inequities for the disease areas we treat. By increasing participation of underrepresented populations in clinical trials, like in Alzheimer’s disease and lupus, we believe we can better serve a diverse range of patients.

Providing Medicines to Those in Need

We strive to meet the needs of patients for the disease areas we treat, including those from underserved and underrepresented groups and in low- and middle-income countries.

Our access programs help treat patients in 39 countries. One example is our Humanitarian Access Program for SPINRAZA in India. In this work, we consider Access to Medicine Index criteria, including:

  • Governance of Access
  • Research and Development
  • Product Delivery

Affordability and Pricing

We strive to remove barriers to care by offering financial assistance and helping secure reimbursement in public and private healthcare programs. In some countries, we have developed tailored solutions to meet local needs.

Biogen’s increasing global operational footprint facilitates reaching more patients and helps us better understand local needs. We have worked with local health authorities and local partners to develop programs to support patients. One example is our value-based agreement in Saudi Arabia.

We regularly review our pricing strategy and prioritize patient access to our therapies. Learn more about our Pricing Principles.

You may also be interested in



Increasing diversity in clinical trials: A collaboration with Tufts Center for the Study of Drug Development


Multiple Sclerosis

The hidden face of MS



Living with lupus: Hazura’s story

Reporting & Principles

2023 Corporate Responsibility Report